CM Management’s Gain Therapeutics GANX Stock Holding History

CM Management’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-90,000	Closed	-$115K	–	67
2024 Q2	$115K	Hold	90,000	–	–	0.11%	63
2024 Q1	$339K	Hold	90,000	–	–	0.29%	59
2023 Q4	$294K	Hold	90,000	–	–	0.24%	67
2023 Q3	$295K	Hold	90,000	–	–	0.31%	56
2023 Q2	$403K	Hold	90,000	–	–	0.39%	58
2023 Q1	$434K	Sell	90,000 -20,000	-18%	-$81.7K	0.52%	48
2022 Q4	$344K	Sell	110,000 -15,000	-12%	-$46.9K	0.41%	56
2022 Q3	$408K	Hold	125,000	–	–	0.46%	59
2022 Q2	$450K	Hold	125,000	–	–	0.48%	59
2022 Q1	$511K	Buy	125,000 +35,000	+39%	+$146K	0.43%	61
2021 Q4	$489K	Buy	90,000 +25,673	+40%	+$177K	0.37%	75
2021 Q3	$479K	Buy	64,327 +54,327	+543%	+$454K	0.36%	76
2021 Q2	$100K	Buy	+10,000	New	+$113K	0.07%	83

Other funds holding GANX

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CM Management's GANX Position: Q3 2024 in Review

CM Management sold out of Gain Therapeutics (GANX) in Q3 2024, closing a stake of 90,000 shares — an estimated $115K sold.

CM Management first reported a position in GANX in Q2 2021 and held it in 13 quarters. The position peaked at $511K in Q1 2022. 19 funds tracked by Wall St. Rank hold GANX as of Q3 2024.

CM Management reported no remaining Gain Therapeutics position as of Q3 2024 after selling out during the quarter.
CM Management sold 90,000 Gain Therapeutics shares in Q3 2024, an estimated $115K.
CM Management first reported a position in Gain Therapeutics in Q2 2021 and held it in 13 quarters.
CM Management's Gain Therapeutics position peaked at $511K in Q1 2022.
19 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2024.

Based on CM Management's 13F filing for Q3 2024, filed 12 Nov 2024.